Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in acute myeloid leukaemia patients

Czech version

Authors: M. Čerňan; T. Szotkowski
Authors‘ workplace: Hemato-onkologická klinika LF UP a FN Olomouc
Published in: Transfuze Hematol. dnes,32, 2026, No. 1, p. 16-21.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd202604

Overview

Allogeneic hematopoietic cell transplantation is the most effective form of consolidation therapy for patients with acute myeloid leukaemia. The combination of venetoclax and azacitidine represents an alternative to initial therapy with lower toxicity and high rate of achieved remissions, enabling subsequent transplantation even in patients initially unsuitable for intensive therapy. The article describes the possibilities of using the combination of venetoclax and azacitidine as a bridge to allogeneic hematopoietic cell transplantation.

Keywords:

acute myeloid leukaemia – venetoclax – azacitidine – bridging therapy – allogeneic transplantation

Sources

1. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009; 113 (18): 4179–4187.

2. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016; 127 (1): 62–70.

3. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140 (12): 1345–1377.

4. Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57 (8): 1217–1239.

5. Jentzsch M, Bischof L, Backhaus D, et al. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv. 2022; 6 (15): 4570–4580.

6. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129 (4): 424–447.

7. Sasaki K, Kadia T, Begna K, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022; 97 (1): 68–78.

8. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30 (21): 2670–2677.

9. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; 126 (3): 291–299.

10. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383 (7): 617–629.

11. Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019; 33 (11): 2599–2609.

12. Vydra J, Ráčil Z, Vítek A, Cetkovský P. Současná role alogenní transplantace krvetvorby v léčbě akutní myeloidní leukemie. Transfuze Hematol Dnes. 2020; 26 (4): 302–309.

13. Wall SA, Devine S, Vasu S. The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years. Blood Rev. 2017; 31 (6): 362–369.

14. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT) -specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106 (8): 2912–2919.

15. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014; 32 (29): 3249–3256.

16. Chen TT, Lin CC, Lo WJ, et al. Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in unfit patients with acute myeloid leukemia. Cancers (Basel). 2024; 16 (6): 1082.

17. Pasvolsky O, Shimony S, Ram R, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Ann Hematol. 2022; 101 (2): 379–387.

18. Dluhošová B, Víšek B, Válka J, et al. Real-world experience with venetoclax-based therapy in acute myeloid leukemia: insights from the Czech Republic. Clin Lymphoma Myeloma Leuk. 2025: S2152-2650 (25) 00237-X.

19. Wen Q, Jiang C, Liu X, et al. Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group. Chin J Cancer Res. 2025; 37 (3): 417–431.

20. Sartor C, Brunetti L, Audisio E, et al. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol. 2023; 202 (3): 599–607.

21. Petit C, Saillard C, Mohty B, et al. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients. Eur J Haematol. 2024; 112 (4): 530–537.

22. Unglaub JM, Schlenk RF, Middeke JM, et al. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML. Blood Adv. 2025; 9 (2): 375–385.

23. Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021; 127 (12): 2049–2061.

24. Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30 (36): 4515–4523.

25. Farag SS, Maharry K, Zhang MJ, et al. Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011; 17 (12): 1796–1803.

26. Yanada M, Yamasaki S, Kondo T. et al. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission. Leukemia. 2024; 38 : 513–520.

PODÍL AUTORŮ NA PŘÍPRAVĚ RUKOPISU

MČ –⁠ hlavní autor, sepsání první a finální verze manuskriptu; TS –⁠ spoluautor, kritická revize rukopisu

PROHLÁŠENÍ

Autor MČ deklaruje podporu vzniku rukopisu, konzultační činnost a cestovní granty od společnosti AbbVie. Autor TS nedeklaruje konflikt zájmů.

DEDIKACE

Práce byla podpořena MZ ČR –⁠ RVO (FNOL, 00098892) a IGA_LF _2025_005.

Do redakce doručeno dne: 10. 11. 2025.

Přijato po recenzi dne: 6. 1. 2026.

MUDr. Martin Čerňan, Ph.D.

Hemato-onkologická klinika

LF UP a FN Olomouc

Zdravotníků 248/7